Page 119 - 2020_09-Haematologica-web

ASLAN003 for differentiation of AML
Foundation and the Ministry of Education under the Research Center of Excellence Program to WJC and NMRC Clinician- Scientist IRG Grant CNIG11nov38 (to JZ). WJC is also sup- ported by a NMRC Clinician Scientist Investigator award.
This study is also partially supported by the RNA Biology Center at CSI Singapore, NUS, by funding with Singapore Ministry of Education’s Tier 3 grants, grant number MOE2014-T3-1-006.
References
1. Heidel FH, Mar BG, Armstrong SA. Self- renewal related signaling in myeloid leukemia stem cells. Int J Hematol. 2011;94(2):109-117.
2. Mack EKM, Marquardt A, Langer D, et al. Comprehensive genetic diagnosis of acute myeloid leukemia by next-generation sequencing. Haematologica. 2019;104(2): 277-287.
3. Misaghian N, Ligresti G, Steelman LS, et al. Targeting the leukemic stem cell: the Holy Grail of leukemia therapy. Leukemia. 2009;23(1):25-42.
4. Zhou J, Chng WJ. Identification and target- ing leukemia stem cells: the path to the cure for acute myeloid leukemia. World J Stem Cells. 2014;6(4):473-484.
5. Zelent A, Guidez F, Melnick A, Waxman S, Licht JD. Translocations of the RARalpha gene in acute promyelocytic leukemia. Oncogene. 2001;20(49):7186-7203.
6. Fasan A, Haferlach C, Perglerova K, Kern W, Haferlach T. Molecular landscape of acute promyelocytic leukemia at diagnosis and relapse. Haematologica. 2017;102(6):e222- e224.
7. Wang ZY, Chen Z. Acute promyelocytic leukemia: from highly fatal to highly cur- able. Blood. 2008;111(5):2505-2515.
8. Nowak D, Stewart D, Koeffler HP. Differentiation therapy of leukemia: 3 decades of development. Blood. 2009;113 (16):3655-3665.
9. Tenen DG. Disruption of differentiation in human cancer: AML shows the way. Nat Rev Cancer. 2003 ;3(2):89-101.
10. Stein EM, DiNardo CD, Pollyea DA, et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood. 2017;130(6):722-731.
11. Huang M, Graves LM. De novo synthesis of pyrimidine nucleotides; emerging interfaces with signal transduction pathways. Cell Mol Life Sci. 2003;60(2):321-336.
12. Reis RAG, Calil FA, Feliciano PR, Pinheiro MP, Nonato MC. The dihydroorotate dehy- drogenases: past and present. Arch Biochem Biophys. 2017;632:175-191.
13. Evans DR, Guy HI. Mammalian pyrimidine biosynthesis: fresh insights into an ancient pathway. J Biol Chem. 2004;279(32):33035- 33038.
14. Bar-Or A, Pachner A, Menguy-Vacheron F, Kaplan J, Wiendl H. Teriflunomide and its mechanism of action in multiple sclerosis.
Drugs. 2014;74(6):659-674.
15. Lolli ML, Sainas S, Pippione AC, et al. Use of
human dihydroorotate dehydrogenase (hDHODH) inhibitors in autoimmune dis- eases and new perspectives in cancer thera- py. Recent Pat Anticancer Drug Discov. 2018;13(1):86-105.
16. Munier-Lehmann H, Vidalain PO, Tangy F, Janin YL. On dihydroorotate dehydrogenas- es and their inhibitors and uses. J Med Chem. 2013;56(8):3148-3167.
17. Sykes DB, Kfoury YS, Mercier FE, et al. Inhibition of dihydroorotate dehydrogenase overcomes differentiation blockade in acute myeloid leukemia. Cell. 2016;167(1):171-186.
18. Dexter DL, Hesson DP, Ardecky RJ, et al. Activity of a novel 4-quinolinecarboxylic acid, NSC 368390 [6-fluoro-2-(2'-fluoro-1,1'- biphenyl-4-yl)-3-methyl-4-quinolinecarb oxylic acid sodium salt], against experimen- tal tumors. Cancer Res. 1985;45(11 Pt 1):5563-5568.
19. Madak JT, Bankhead A 3rd, Cuthbertson CR, Showalter HD, Neamati N. Revisiting the role of dihydroorotate dehydrogenase as a therapeutic target for cancer. Pharmacol Ther. 2019;195:111-131.
20. Zhou J, Lu X, Tan TZ, Chng WJ. X-linked inhibitor of apoptosis inhibition sensitizes acute myeloid leukemia cell response to TRAIL and chemotherapy through potenti- ated induction of proapoptotic machinery. Mol Oncol. 2018;12(1):33-47.
21. Zhou J, Bi C, Janakakumara JV, et al. Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AML. Blood. 2009;113(17):4052- 4062.
22. Debatin KM, Stahnke K, Fulda S. Apoptosis in hematological disorders. Semin Cancer Biol. 2003;13(2):149-158.
23. Avouac J, Palumbo K, Tomcik M, et al. Inhibition of activator protein 1 signaling abrogates transforming growth factor beta- mediated activation of fibroblasts and pre- vents experimental fibrosis. Arthritis Rheum. 2012;64(5):1642-1652.
24. Sykes DB. The emergence of dihydroorotate dehydrogenase (DHODH) as a therapeutic target in acute myeloid leukemia. Expert Opin Ther Targets. 2018;22(11):893-898.
25. Pally C, Smith D, Jaffee B, et al. Side effects of brequinar and brequinar analogues, in combination with cyclosporine, in the rat. Toxicology. 1998;127(1-3):207-222.
26. Arteaga CL, Brown TD, Kuhn JG, et al. Phase I clinical and pharmacokinetic trial of
brequinar sodium (DuP 785; NSC 368390).
Cancer Res. 1989;49(16):4648-4653.
27. Cao L, Weetall M, Trotta C, et al. Targeting of hematologic malignancies with PTC299, a novel potent inhibitor of dihydroorotate dehydrogenase with favorable pharmaceuti- cal properties. Mol Cancer Ther. 2019;18
(1):3-16.
28. WuD,WangW,ChenW,etal.
Pharmacological inhibition of dihydroorotate dehydrogenase induces apoptosis and differ- entiation in acute myeloid leukemia cells. Haematologica. 2018;103(9):1472-1483.
29. Christian S, Merz C, Evans L, et al. The novel dihydroorotate dehydrogenase (DHODH) inhibitor BAY 2402234 triggers differentiation and is effective in the treat- ment of myeloid malignancies. Leukemia. 2019;33(10):2403-2415.
30. Girardi T, De Keersmaecker K. T-ALL: ALL a matter of translation? Haematologica. 2015;100(3):293-295.
31. Topisirovic I, Guzman ML, McConnell MJ, et al. Aberrant eukaryotic translation initia- tion factor 4E-dependent mRNA transport impedes hematopoietic differentiation and contributes to leukemogenesis. Mol Cell Biol. 2003;23(24):8992-9002.
32. Shahbazian D, Parsyan A, Petroulakis E, et al. Control of cell survival and proliferation by mammalian eukaryotic initiation factor 4B. Mol Cell Biol. 2010;30(6):1478-1485.
33. Assouline S, Culjkovic B, Cocolakis E, et al. Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of- principle clinical trial with ribavirin. Blood. 2009;114(2):257-260.
34. Hess J, Angel P, Schorpp-Kistner M. AP-1 subunits: quarrel and harmony among sib- lings. J Cell Sci. 2004;117(Pt 25):5965-5973.
35. Liebermann DA, Gregory B, Hoffman B. AP- 1 (Fos/Jun) transcription factors in hematopoietic differentiation and apoptosis. Int J Oncol. 1998;12(3):685-700.
36. Passegue E, Wagner EF, Weissman IL. JunB deficiency leads to a myeloproliferative dis- order arising from hematopoietic stem cells. Cell. 2004;119(3):431-443.
37. Brach MA, Herrmann F, Kufe DW. Activation of the AP-1 transcription factor by arabinofuranosylcytosine in myeloid leukemia cells. Blood. 1992;79(3):728-734.
38. Shafarenko M, Amanullah A, Gregory B, Liebermann DA, Hoffman B. Fos modulates myeloid cell survival and differentiation and partially abrogates the c-Myc block in termi- nal myeloid differentiation. Blood. 2004;103 (11):4259-4267.
haematologica | 2020; 105(9)
2297